title: Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
abstract: BACKGROUND
  The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment.
  
  
  METHODS
  One hundred and twenty patients were included. Blood samples were collected before treatment and 3 weeks later before the next treatment cycle. Plasma TIMP-1 and serum CEA levels were correlated to treatment outcome.
  
  
  RESULTS
  No significant associations between baseline TIMP-1 or CEA levels and best response to treatment or progression-free survival (PFS) could be demonstrated. In contrast, high baseline plasma TIMP-1 levels were associated with poor overall survival (OS), P = 0.008, hazard ratio (HR) = 1.80 [95% confidence interval (CI): 1.17-2.78]. Furthermore, increase in TIMP-1 levels from baseline to immediately before the second cycle of chemotherapy had a significant negative effect on survival (P = 0.03, HR = 1.30, 95% CI: 1.02-1.65) while a decrease in TIMP-1 was significantly associated with a higher objective response rate (P = 0.03).
  
  
  CONCLUSIONS
  Both high baseline and subsequent increase in TIMP-1 levels were associated with shorter OS in patients with mCRC receiving XELOX as first-line treatment, whereas baseline TIMP-1 levels were not associated with response or PFS following XELOX treatment.
authors.affiliation: Department of Surgical Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark. frederiksen@dadlnet.dk
authors.forename: C
authors.initials: C
authors.lastname: Frederiksen
authors.forename: C
authors.initials: C
authors.lastname: Qvortrup
authors.forename: I J
authors.initials: IJ
authors.lastname: Christensen
authors.forename: B
authors.initials: B
authors.lastname: Glimelius
authors.forename: A
authors.initials: A
authors.lastname: Berglund
authors.forename: B V
authors.initials: BV
authors.lastname: Jensen
authors.forename: S E
authors.initials: SE
authors.lastname: Nielsen
authors.forename: N
authors.initials: N
authors.lastname: Keldsen
authors.forename: H J
authors.initials: HJ
authors.lastname: Nielsen
authors.forename: N
authors.initials: N
authors.lastname: Brünner
authors.forename: P
authors.initials: P
authors.lastname: Pfeiffer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010071:Oxaloacetates; D016019:Survival Analysis; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D010071:Oxaloacetates; D019715:Tissue Inhibitor of Metalloproteinase-1; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil